- Home
- FSP vs LRMR Comparison
FSP vs LRMR Comparison
Compare FSP & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- LRMR
- Stock Information
- Founded
- FSP 1981
- LRMR N/A
- Country
- FSP United States
- LRMR United States
- Employees
- FSP N/A
- LRMR N/A
- Industry
- FSP Real Estate Investment Trusts
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- LRMR Health Care
- Exchange
- FSP Nasdaq
- LRMR Nasdaq
- Market Cap
- FSP 159.5M
- LRMR 183.8M
- IPO Year
- FSP N/A
- LRMR N/A
- Fundamental
- Price
- FSP $1.53
- LRMR $2.12
- Analyst Decision
- FSP
- LRMR Strong Buy
- Analyst Count
- FSP 0
- LRMR 9
- Target Price
- FSP N/A
- LRMR $19.00
- AVG Volume (30 Days)
- FSP 285.2K
- LRMR 1.4M
- Earning Date
- FSP 04-29-2025
- LRMR 04-30-2025
- Dividend Yield
- FSP 2.65%
- LRMR N/A
- EPS Growth
- FSP N/A
- LRMR N/A
- EPS
- FSP N/A
- LRMR N/A
- Revenue
- FSP $115,994,000.00
- LRMR N/A
- Revenue This Year
- FSP $4.36
- LRMR N/A
- Revenue Next Year
- FSP $0.81
- LRMR N/A
- P/E Ratio
- FSP N/A
- LRMR N/A
- Revenue Growth
- FSP N/A
- LRMR N/A
- 52 Week Low
- FSP $1.36
- LRMR $1.61
- 52 Week High
- FSP $2.21
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- FSP 43.75
- LRMR 44.72
- Support Level
- FSP $1.49
- LRMR $2.03
- Resistance Level
- FSP $1.60
- LRMR $2.33
- Average True Range (ATR)
- FSP 0.07
- LRMR 0.30
- MACD
- FSP 0.01
- LRMR -0.01
- Stochastic Oscillator
- FSP 28.12
- LRMR 11.21
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.